Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes : Results from the SELECT trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10327846" target="_blank" >RIV/00064165:_____/16:10327846 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10327846

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.msard.2016.02.001" target="_blank" >http://dx.doi.org/10.1016/j.msard.2016.02.001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2016.02.001" target="_blank" >10.1016/j.msard.2016.02.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes : Results from the SELECT trial

Popis výsledku v původním jazyce

Background: The SELECT study demonstrated superior effects of daclizumab high-yield process (DAC HYP) to placebo in key endpoints in patients with relapsing and remitting multiple sclerosis (RRMS). Objective: To assess the impact of DAC HYP and disease activity on health-related quality of life (HRQoL) using data from this study. Methods: HRQoL was assessed at baseline, 12, 24, and 52 weeks using the Multiple Sclerosis Impact Scale (MSIS-29), the 12-items Short Form Health Survey, and the EuroQoL-5 Dimensions. An analysis of covariance model was used to compare treatment difference in change from baseline. Mixed-effects models were used to assess the impact of disability progression, relapse, treatment, and interaction between treatment and these events on HRQoL outcome. Results: DAC HYP 150 mg resulted in significant positive impacts on HRQoL compared to placebo. It was also found to significantly reduce the adverse impact of relapse on the MSIS-29 physical scale (-12.45; p=0.0006). Relapse and disability progression were significantly associated with impaired HRQoL. Conclusion: DAC HYP 150 mg improved HRQoL in patients with RRMS compared to placebo. The treatment benefit can be partially attributed to reduction in disease activity and attenuation of the adverse impact of relapse on HRQoL.

Název v anglickém jazyce

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes : Results from the SELECT trial

Popis výsledku anglicky

Background: The SELECT study demonstrated superior effects of daclizumab high-yield process (DAC HYP) to placebo in key endpoints in patients with relapsing and remitting multiple sclerosis (RRMS). Objective: To assess the impact of DAC HYP and disease activity on health-related quality of life (HRQoL) using data from this study. Methods: HRQoL was assessed at baseline, 12, 24, and 52 weeks using the Multiple Sclerosis Impact Scale (MSIS-29), the 12-items Short Form Health Survey, and the EuroQoL-5 Dimensions. An analysis of covariance model was used to compare treatment difference in change from baseline. Mixed-effects models were used to assess the impact of disability progression, relapse, treatment, and interaction between treatment and these events on HRQoL outcome. Results: DAC HYP 150 mg resulted in significant positive impacts on HRQoL compared to placebo. It was also found to significantly reduce the adverse impact of relapse on the MSIS-29 physical scale (-12.45; p=0.0006). Relapse and disability progression were significantly associated with impaired HRQoL. Conclusion: DAC HYP 150 mg improved HRQoL in patients with RRMS compared to placebo. The treatment benefit can be partially attributed to reduction in disease activity and attenuation of the adverse impact of relapse on HRQoL.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis and Related Disorders

ISSN

2211-0348

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

March

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

66-72

Kód UT WoS článku

000375044800012

EID výsledku v databázi Scopus

2-s2.0-84962536674